Bank of Montreal
ADAP

Bank of Montreal’s Adaptimmune Therapeutics ADAP Stock Holding History

Bank of Montreal’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-660
Closed -$3K – 3637
2021
Q1 		$3K Buy
+660
New +$3.78K ﹤0.01% 4799

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of Montreal's ADAP Position: Q2 2021 in Review

Bank of Montreal sold out of Adaptimmune Therapeutics (ADAP) in Q2 2021, closing a stake of 660 shares — an estimated $3K sold.

Bank of Montreal first reported a position in ADAP in Q1 2021 and held it in 1 quarter. The position peaked at $3K in Q1 2021. 82 funds tracked by Wall St. Rank hold ADAP as of Q2 2021.

  • Bank of Montreal reported no remaining Adaptimmune Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Bank of Montreal sold 660 Adaptimmune Therapeutics shares in Q2 2021, an estimated $3K.
  • Bank of Montreal first reported a position in Adaptimmune Therapeutics in Q1 2021 and held it in 1 quarter.
  • Bank of Montreal's Adaptimmune Therapeutics position peaked at $3K in Q1 2021.
  • 82 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2021.

Based on Bank of Montreal's 13F filing for Q2 2021, filed 12 Aug 2021.